$ 4.52
Key Takeaways
Risk factor
Very high price volatility
Profitability factor
Undervalued vs peers
About
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag...
Company Valuation
Considering past and projected metrics, the stock is 'cheaper' than its peers. Specifically, the stock is overvalued on EV/EBITDA, underpriced on P/FC.
Target Price
The average target price of VNDA is 13 and suggests 201% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas
